Klott (Human Coagulation Factor Viii)

Human coagulation factor VIII in Klott serves as a cofactor for activated factor IX, accelerating the conversion of factor X to Xa within the intrinsic coagulation pathway. This restores the cascade's ability to generate thrombin, leading to fibrin clot formation and effective control of bleeding.

The dosage of Klott is individualized and determined by the prescribing healthcare professional based on the patient’s factor VIII activity level, severity of hemophilia, weight, and clinical situation. Only a qualified clinician should set the appropriate dosing regimen.

Safety data for Klott in pregnancy and lactation are limited. Use is generally reserved for cases where the potential benefit to the mother outweighs any possible risk to the fetus or infant. Treatment decisions should be made by a specialist in consultation with the patient.

To order Klott, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the team will respond with pricing, availability, cold‑chain shipping details and necessary import documentation.

Klott is a human-derived factor VIII concentrate administered intravenously, similar in function to recombinant factor VIII products. Compared with recombinant forms, Klott may have a different immunogenic profile and manufacturing process, but both aim to replace deficient factor VIII. Choice of product depends on clinical factors, availability, and physician preference.

Klott must be stored at 2‑8 °C in a refrigerator. It should be kept in its original container, protected from light, and must not be frozen or shaken. Proper cold‑chain handling is essential to maintain product stability and efficacy.

Klott is given as an intravenous infusion. The healthcare provider prepares the dose in a sterile container and administers it through a vein, typically using an infusion pump or controlled syringe. Administration is performed under medical supervision to monitor for any immediate reactions.

The most serious risks include the development of inhibitory antibodies that neutralize factor VIII activity, severe allergic or anaphylactic reactions, and thromboembolic events from excessive clotting. Patients should be monitored closely for signs of these complications, especially during the initial treatment period.

Klott should not be used in individuals with a known hypersensitivity to human factor VIII or any excipients in the formulation. Patients with a history of severe allergic reactions to blood‑derived products, or those with active thrombotic disorders where additional clotting factor could exacerbate the condition, should avoid its use.